Glutaredoxin-1 alleviates acetaminophen-induced liver injury by decreasing its toxic metabolites

Ying Xu; Yan Xia; Qinhui Liu; Xiandan Jing; Qin Tang; Jinhang Zhang; Qingyi Jia; Zijing Zhang; Jiahui Li; Jiahao Chen; Yimin Xiong; Yanping Li; Jinhan He

doi:10.1016/j.jpha.2023.08.004

Volume 13 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2023 > 13(12): 1548-1561

Ying Xu, Yan Xia, Qinhui Liu, Xiandan Jing, Qin Tang, Jinhang Zhang, Qingyi Jia, Zijing Zhang, Jiahui Li, Jiahao Chen, Yimin Xiong, Yanping Li, Jinhan He. Glutaredoxin-1 alleviates acetaminophen-induced liver injury by decreasing its toxic metabolites[J]. Journal of Pharmaceutical Analysis, 2023, 13(12): 1548-1561. doi: 10.1016/j.jpha.2023.08.004

Citation:

Ying Xu, Yan Xia, Qinhui Liu, Xiandan Jing, Qin Tang, Jinhang Zhang, Qingyi Jia, Zijing Zhang, Jiahui Li, Jiahao Chen, Yimin Xiong, Yanping Li, Jinhan He. Glutaredoxin-1 alleviates acetaminophen-induced liver injury by decreasing its toxic metabolites[J]. Journal of Pharmaceutical Analysis, 2023, 13(12): 1548-1561. doi: 10.1016/j.jpha.2023.08.004

Citation:

Ying Xu, Yan Xia, Qinhui Liu, Xiandan Jing, Qin Tang, Jinhang Zhang, Qingyi Jia, Zijing Zhang, Jiahui Li, Jiahao Chen, Yimin Xiong, Yanping Li, Jinhan He. Glutaredoxin-1 alleviates acetaminophen-induced liver injury by decreasing its toxic metabolites[J]. Journal of Pharmaceutical Analysis, 2023, 13(12): 1548-1561. doi: 10.1016/j.jpha.2023.08.004

PDF( 4326 KB)

Glutaredoxin-1 alleviates acetaminophen-induced liver injury by decreasing its toxic metabolites

doi: 10.1016/j.jpha.2023.08.004

Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China

Funds:

This study was supported by the National Natural Science Foundation of China (Grant Nos.: 82025007, 81930020, and 82170874) and China Postdoctoral Science Foundation (Grant No.: 2022M710099). We appreciate professor Yao Chen and Jing Guo (Department of Clinical Pharmacology, Xiangya Hospital, Central South University) for their experimental supports, and Qianlun Pu (Advance Mass Spectrometry Center, West China hospital, Sichuan University) for the technical support.

Received Date: Apr. 21, 2023
Accepted Date: Aug. 07, 2023
Rev Recd Date: Jul. 06, 2023
Publish Date: Aug. 09, 2023

Abstract

Abstract

Excessive N-acetyl-p-benzoquinone imine (NAPQI) formation is a starting event that triggers oxidative stress and subsequent hepatocyte necrosis in acetaminophen (APAP) overdose caused acute liver failure (ALF). S-glutathionylation is a reversible redox post-translational modification and a prospective mechanism of APAP hepatotoxicity. Glutaredoxin-1 (Glrx1), a glutathione-specific thioltransferase, is a primary enzyme to catalyze deglutathionylation. The objective of this study was to explored whether and how Glrx1 is associated with the development of ALF induced by APAP. The Glrx1 knockout mice (Glrx1) and liver-specific overexpression of Glrx1 (AAV8-Glrx1) mice were produced and underwent APAP-induced ALF. Pirfenidone (PFD), a potential inducer of Glrx1, was administrated preceding APAP to assess its protective effects. Our results revealed that the hepatic total protein S-glutathionylation (PSSG) increased and the Glrx1 level reduced in mice after APAP toxicity. Glrx1^−/− mice were more sensitive to APAP overdose, with higher oxidative stress and more toxic metabolites of APAP. This was attributed to Glrx1 deficiency increasing the total hepatic PSSG and the S-glutathionylation of cytochrome p450 3a11 (Cyp3a11), which likely increased the activity of Cyp3a11. Conversely, AAV8-Glrx1 mice were defended against liver damage caused by APAP overdose by inhibiting the S-glutathionylation and activity of Cyp3a11, which reduced the toxic metabolites of APAP and oxidative stress. PFD precede administration upregulated Glrx1 expression and alleviated APAP-induced ALF by decreasing oxidative stress. We have identified the function of Glrx1 mediated PSSG in liver injury caused by APAP overdose. Increasing Glrx1 expression may be investigated for the medical treatment of APAP-caused hepatic injury.
- Glutaredoxin-1,
- S-glutathionylation,
- Acetaminophen,
- Toxic metabolites,
- Cyp3a11

FullText(HTML)

References(48)

References

[1]	W. Bernal, G. Auzinger, A. Dhawan, et al., Acute liver failure, Lancet 376 (2010) 190-201.
[2]	A. Reuben, H. Tillman, R.J. Fontana, et al., Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study, Ann. Intern. Med. 164 (2016) 724-732.
[3]	A. Long, M. Magrath, M. Mihalopoulos, et al., Changes in epidemiology of acetaminophen overdoses in an urban county hospital after 20 years, Am. J. Gastroenterol. 117 (2022) 1324-1328.
[4]	A. Bertolini, I.P. van de Peppel, F.A.J.A Bodewes, et al., Abnormal liver function tests in patients with COVID-19: Relevance and potential pathogenesis, Hepatology 72 (2020) 1864-1872.
[5]	R.E. Moss, E.H. Hertzberg, H. Person, et al., Increase in rate of hospitalizations for pediatric intentional acetaminophen ingestion at a single center during the COVID-19 pandemic, Clin. Pediatr. 62 (2023) 295-300.
[6]	M.R. McGill, H. Jaeschke, Metabolism and disposition of acetaminophen: Recent advances in relation to hepatotoxicity and diagnosis, Pharm. Res. 30 (2013) 2174-2187.
[7]	K. Du, A. Ramachandran, H. Jaeschke, Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and therapeutic potential, Redox Biol. 10 (2016) 148-156.
[8]	A. Ramachandran, H. Jaeschke, Acetaminophen hepatotoxicity, Semin. Liver Dis. 39 (2019) 221-234.
[9]	B.H. Rumack, D.N. Bateman, Acetaminophen and acetylcysteine dose and duration: Past, present and future, Clin. Toxicol. 50 (2012) 91-98.
[10]	A. Licata, M.G. Minissale, S. Stankevičiūtė, et al., N-acetylcysteine for preventing acetaminophen-induced liver injury: A comprehensive review, Front. Pharmacol. 13 (2022), 828565.
[11]	J.C.Y. Chan, A.C.K. Soh, D.Y.Q. Kioh, et al., Reactive metabolite-induced protein glutathionylation: A potentially novel mechanism underlying acetaminophen hepatotoxicity, Mol. Cell. Proteom. 17 (2018) 2034-2050.
[12]	X. Yang, J. Greenhaw, A. Ali, et al., Changes in mouse liver protein glutathionylation after acetaminophen exposure, J. Pharmacol. Exp. Ther. 340 (2012) 360-368.
[13]	D.J. McGarry, P. Chakravarty, C.R. Wolf, et al., Altered protein S-glutathionylation identifies a potential mechanism of resistance to acetaminophen-induced hepatotoxicity, J. Pharmacol. Exp. Ther. 355 (2015) 137-144.
[14]	A. Musaogullari, Y.C. Chai, Redox regulation by protein S-glutathionylation: From molecular mechanisms to implications in health and disease, Int. J. Mol. Sci. 21 (2020), 8113.
[15]	R. Matsui, B. Ferran, A. Oh, et al., Redox regulation via glutaredoxin-1 and protein S-glutathionylation, Antioxid. Redox Signal. 32 (2020) 677-700.
[16]	J.J. Mieyal, M.M. Gallogly, S. Qanungo, et al., Molecular mechanisms and clinical implications of reversible protein S-glutathionylation, Antioxid. Redox Signal. 10 (2008) 1941-1988.
[17]	Y. Xi, Y. Li, P. Xu, et al., The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1, Sci. Adv. 7 (2021), eabg9241.
[18]	D. Shao, J. Han, X. Hou, et al., Glutaredoxin-1 deficiency causes fatty liver and dyslipidemia by inhibiting sirtuin-1, Antioxid. Redox Sign. 27 (2017) 313-327.
[19]	M.I. Ahmad, M.U. Ijaz, M. Hussain, et al., High fat diet incorporated with meat proteins changes biomarkers of lipid metabolism, antioxidant activities, and the serum metabolomic profile in Glrx1-/- mice, Food Funct. 11 (2020) 236-252.
[20]	X. Sun, C. Ye, Q. Deng, et al., Contribution of glutaredoxin-1 to Fas S-glutathionylation and inflammation in ethanol-induced liver injury, Life Sci. 264 (2021), 118678.
[21]	K. Seidel, X. Wan, M. Zhang, et al., Alcohol binge drinking selectively stimulates protein S-glutathionylation in aorta and liver of ApoE-/- mice, Front. Cardiovasc. Med. 8 (2021), 649813.
[22]	S. Pu, L. Ren, Q. Liu, et al., Loss of 5-lipoxygenase activity protects mice against paracetamol- induced liver toxicity, Br. J. Pharmacol. 173 (2016) 66-76.
[23]	J. Yan, Q. Liu, Q. Tang, et al., Mesencephalic astrocyte-derived neurotrophic factor alleviates non-alcoholic steatohepatitis induced by Western diet in mice, FASEB J. 36 (2022), e22349.
[24]	J. Guo, Y. Xu, L. Chen, et al., Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug, J. Adv. Res. 39 (2022) 319-332.
[25]	E. Seki, D.A. Brenner, M. Karin, A liver full of JNK: Signaling in regulation of cell function and disease pathogenesis, and clinical approaches, Gastroenterology 143 (2012) 307-320.
[26]	B.L. Woolbright, H. Jaeschke, Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure, J. Hepatol. 66 (2017) 836-848.
[27]	F.A. Schuran, C. Lommetz, A. Steudter, et al., Aryl hydrocarbon receptor activity in hepatocytes sensitizes to hyperacute acetaminophen-induced hepatotoxicity in mice, Cell. Mol. Gastroenterol. Hepatol. 11 (2021) 371-388.
[28]	Y. Wang, P. Wang, Y. Zhang, et al., Decreased expression of the host long-noncoding RNA-GM facilitates viral escape by inhibiting the kinase activity TBK1 via S-glutathionylation, Immunity 53 (2020) 1168-1181.
[29]	M. Okuda, N. Inoue, H. Azumi, et al., Expression of glutaredoxin in human coronary arteries, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1483-1487.
[30]	N. Rouhier, J. Couturier, M.K. Johnson, et al., Glutaredoxins: Roles in iron homeostasis, Trends Biochem. Sci. 35 (2010) 43-52.
[31]	C. Saito, C. Zwingmann, H. Jaeschke, Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine, Hepatology 51 (2010) 246-254.
[32]	S. Win, T.A. Than, R.W.M Min, et al., C-Jun N-terminal kinase mediates mouse liver injury through a novel Sab (SH3BP5)-dependent pathway leading to inactivation of intramitochondrial Src, Hepatology 63 (2016) 1987-2003.
[33]	A. Ramachandran, H. Jaeschke, A mitochondrial journey through acetaminophen hepatotoxicity, Food Chem. Toxicol. 140 (2020), 111282.
[34]	A.A. Widjaja, J. Dong, E. Adami, et al., Redefining IL11 as a regeneration-limiting hepatotoxin and therapeutic target in acetaminophen-induced liver injury, Sci. Transl. Med. 13 (2021), eaba8146.
[35]	L.P. James, P.R. Mayeux, J.A. Hinson, Acetaminophen-induced hepatotoxicity, Drug Metab. Dispos. 31 (2003) 1499-1506.
[36]	E. Yoon, A. Babar, M. Choudhary, et al., Acetaminophen-induced hepatotoxicity: A comprehensive update, J. Clin. Transl. Hepatol. 4 (2016) 131-142.
[37]	P. Xu, Y. Xi, P. Wang, et al., Inhibition of p53 sulfoconjugation prevents oxidative hepatotoxicity and acute liver failure, Gastroenterology 162 (2022) 1226-1241.
[38]	Y.An, P. Wang, P. Xu, et al., An unexpected role of cholesterol sulfotransferase and its regulation in sensitizing mice to acetaminophen-induced liver injury, Mol. Pharmacol. 95 (2019) 597-605.
[39]	T. Zhang, F. Yu, L. Guo, et al., Small heterodimer partner regulates circadian cytochromes p450 and drug-induced hepatotoxicity, Theranostics 8 (2018) 5246-5258.
[40]	A. Vonada, A. Tiyaboonchai, S. Nygaard, et al., Therapeutic liver repopulation by transient acetaminophen selection of gene-modified hepatocytes, Sci. Transl. Med. 13 (2021), eabg3047.
[41]	S. Vrettou, B. Wirth, S-glutathionylation and S-nitrosylation in mitochondria: Focus on homeostasis and neurodegenerative diseases, Int. J. Mol. Sci. 23 (2022), 15849.
[42]	R.J. Mailloux, J.R. Treberg, Protein S-glutathionlyation links energy metabolism to redox signaling in mitochondria, Redox Biol. 8 (2016) 110-118.
[43]	J. Li, P. Cheng, S. Li, et al., Selenium status in diet affects acetaminophen-induced hepatotoxicity via interruption of redox environment, Antioxid. Redox Signal. 34 (2021) 1355-1367.
[44]	F.T. Ogata, V. Branco, F.F. Vale, et al., Glutaredoxin: Discovery, redox defense and much more, Redox Biol. 43 (2021), 101975.
[45]	V. Anathy, S.W. Aesif, A.S. Guala, et al., Redox amplification of apoptosis by caspase-dependent cleavage of glutaredoxin 1 and S-glutathionylation of Fas, J. Cell Biol. 184 (2009) 241-252.
[46]	K. Dong, M. Wu, X. Liu, et al., Glutaredoxins concomitant with optimal ROS activate AMPK through S-glutathionylation to improve glucose metabolism in type 2 diabetes, Free Radic. Biol. Med. 101 (2016) 334-347.
[47]	G. Sgalla, E. Cocconcelli, R. Tonelli, et al., Novel drug targets for idiopathic pulmonary fibrosis, Expert Rev. Respir. Med. 10 (2016) 393-405.
[48]	L.H. Lancaster, J.A. de Andrade, J.D. Zibrak, et al., Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis, Eur. Respir. Rev. 26 (2017), 170057.